Table 3. DRI values for growth inhibition by RG7388/Nutlin-3 in combination with cisplatin for the wild-type ovarian cancer cell lines.
| Cell Line | Combination | Component | DRI | ||||
|---|---|---|---|---|---|---|---|
| XGI50 | |||||||
| 0.25 | 0.5 | 1 | 2 | 4 | |||
| A2780 | Nut-3+CDDP | Nut-3 | 2.6 | 5.7 | 5.5 | 4.3 | 2.6 |
| CDDP | 4.3 | 6.9 | 6.4 | 5.2 | 3.2 | ||
| RG+CDDP | RG7388 | 1.2 | 3.3 | 4.3 | 5.0 | 3.2 | |
| CDDP | 3.3 | 4.5 | 3.7 | 3.0 | 1.7 | ||
| IGROV-1 | Nut-3+CDDP | Nut-3 | 2.3 | 3.2 | 2.5 | 1.6 | 1.2 |
| CDDP | 2.9 | 2.8 | 1.8 | 1.1 | 0.7 | ||
| RG+CDDP | RG7388 | 1.8 | 2.5 | 5.5 | 6.2 | 4.5 | |
| CDDP | 3.6 | 2.4 | 1.8 | 1.1 | 0.6 | ||
| OAW42 | Nut-3+CDDP | Nut-3 | 1.5 | 1.6 | 1.4 | 1.1 | 1.5 |
| CDDP | 3.6 | 2.9 | 2.0 | 1.4 | 1.3 | ||
| RG+CDDP | RG7388 | 2.2 | 2.1 | 1.6 | 1.1 | 0.7 | |
| CDDP | 4.5 | 3.2 | 2.0 | 1.2 | 0.7 | ||
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. DRI values were calculated for each constant ratio combination from the average of at least three independent experiments. Favorable DRI values are highlighted in bold font. Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; DRI, Dose Reduction Index.